{
    "clinical_study": {
        "@rank": "136079", 
        "acronym": "CTO-201", 
        "arm_group": [
            {
                "arm_group_label": "collagenase", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "saline", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "A prospective, multi-center, double blind, 2 stage, placebo-controlled, phase II study,\n      evaluating acute intra-coronary injected collagenase prior to routine standard-of-care\n      percutaneous revascularization procedures in subjects with chronic total coronary artery\n      occlusions (CTOs)."
        }, 
        "brief_title": "Collagenase Total Occlusion Trial", 
        "condition": "Chronic Total Occlusions", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or females patients > 18 years of age who has a clinically driven, planned PCI\n             of the target CTO, in a major epicardial coronary artery, without planned\n             revascularization of other coronary stenosis/stenoses in major epicardial segments.\n\n          -  Target CTO must be greater than or equal to 3 calendar months prior to Screening\n\n          -  Target CTO must meet protocol defined criteria for entry\n\n          -  Patient is receiving a course of optimal anti-ischemic medical therapy (at least 2\n             anti-anginal agents or the maximum tolerated anti-anginal therapy)\n\n        Exclusion Criteria:\n\n          -  Documented chest radiation exposure > 4.0 Gray within 8 weeks of Day 0\n\n          -  Target vessel is not an occluded stent, saphenous vein graft\n\n          -  Patient had ACS < 4 weeks from Screening, attributable to any coronary vessel\n\n          -  Patient has non-healed dissection plane extending to a point adjacent to the coronary\n             lumen distal to the target CTO\n\n          -  Patient has a known or suspected target vessel perforation within 30 days of Day 0\n\n          -  Angiographic exclusion criteria as defined in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753180", 
            "org_study_id": "CTO-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "collagenase", 
                "description": "Local intra-coronary administration of MZ-004 at or into the CTO", 
                "intervention_name": "collagenase", 
                "intervention_type": "Biological", 
                "other_name": "MZ-004"
            }, 
            {
                "arm_group_label": "saline", 
                "description": "Local intra-coronary administration of saline at or into the CTO", 
                "intervention_name": "saline", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CTO", 
            "PCI", 
            "Angioplasty"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "number_of_arms": "2", 
        "official_title": "A 2-stage Study to Evaluate Single Doses of MZ-004 at Different Dose Levels in Patients With Chronic Total Occlusions. Stage 1: Open Label Training Stage. Stage 2: Double-blind, Randomized, Placebo-Controlled Stage", 
        "overall_contact": {
            "email": "laura.agensky@matrizyme.com", 
            "last_name": "Laura Agensky, MBA", 
            "phone": "1-905-771-0333", 
            "phone_ext": "100"
        }, 
        "overall_contact_backup": {
            "last_name": "Allison Manners", 
            "phone": "1-905-771-0333", 
            "phone_ext": "102"
        }, 
        "overall_official": {
            "affiliation": "St. Michael's Hospital, Toronto, Ontario, Canada", 
            "last_name": "Christopher Buller, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration", 
                "Netherlands: Dutch Healthcare Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the PCI success rates in CTOs that have failed a previous PCI attempt between different doses of MZ-004 and placebo", 
            "measure": "Anterograde PCI success rate for patients with a target CTO", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 of study procedures"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753180"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the total fluoroscopy time between patients treated with two different doses of MZ-004 and/or placebo", 
                "measure": "Total fluoroscopy time", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 and Day 1 of study procedures"
            }, 
            {
                "description": "To assess the total procedural time between patients treated with two different doses of MZ-004 and/or placebo", 
                "measure": "Total PCI procedural time", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 of study procedures"
            }, 
            {
                "description": "To assess the percentage of lesions that are crossed with soft guide wires post study drug administration", 
                "measure": "Soft wire crossing", 
                "safety_issue": "No", 
                "time_frame": "Day 1 study procedures"
            }, 
            {
                "description": "To assess the overall safety of the procedure in evaluating treatment emergent adverse events, major adverse cardiac events, radiation exposure, angiographic complications, ECGs, vital signs and clinical laboratory parameters", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0, Day 1 and Day 2 of study procedures"
            }
        ], 
        "source": "Matrizyme Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Matrizyme Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}